Many cationic amphiphilic (phospholipidosis-inducing) drugs (CADs) accumulate in tissues following repeated dosing in preclinical models, and this is sometimes associated with dose-limiting toxicities. Plasma drug levels cannot be used to estimate tissue accumulation of CADs since it occurs in tissues despite stabilization of plasma levels. Severe myopathy was found in skeletal muscles of rats during the initial safety evaluation of a dopamine D3 receptor antagonist, PNU-177864, and was associated with phospholipidosis in numerous tissues. The myopathy was observed only when plasma levels of PNU-177864 remained essentially constant throughout the 24-hour dosing period. A repeat dose drug distribution study using whole body autoradiography demonstrated that drug-related material did not accumulate in skeletal muscle or other tissues following repeated doses at levels considered within the therapeutic range and showing toxicokinetic profiles acceptable for further development. These observations provided support for the continued development of and longer-term toxicity studies with this candidate compound.
INTRODUCTION
Numerous compounds with a variety of pharmacological indications cause accumulation of phospholipids in lysosomes of humans and animals. These compounds, frequently referred to as cationic amphiphilic drugs (CADs), share common structural features, i.e., a hydrophobic component consisting of an aromatic or aliphatic ring structure often substituted with one or more halogen atoms and a hydrophilic region containing a primary or substituted amino group uncharged at physiological pH, but charged at low pH (Reasor, 1989; Whitehouse et al., 1994; Horn et al., 1996; Reasor et al., 1996) . The CADs alter the metabolism of membrane phospholipids resulting in the formation of multilamellar membranous bodies in lysosomes of affected cells. These bodies, referred to as lysosomal lamellar bodies (LLBs), are considered hallmarks of drug-induced phospholipidosis (Reasor, 1989) .
The association or lack of an association between phospholipidosis, lysosomal drug accumulation, and cellular injury has been the subject of much attention (Horn et al., 1996) . High or prolonged exposures to phospholipidosisinducing drugs may lead to dose-limiting toxicities, including nephrotoxicity with aminoglycoside antibiotics (Kaloyanides and Pastoriza-Munoz, 1980) , pulmonary toxicity with amiodarone (Costa-Jussà et al., 1984; Riva et al., 1987) , and myopathy and retinopathy with chloroquine (Finbloom et al., 1985) . Repeated dosing with many CADs is accompanied by accumulation of drug or metabolites in tissues, and this parallels increases in phospholipid and numbers of LLBs in affected tissues (Kaloyanides and Pastoriza-Munoz, 1980; Riva et al., 1987; Heyneman and Reasor, 1986; Kannan et al., 1989; Reasor et al., 1990; Kannan et al., 1991) . Drug accumulation proceeding in parallel with the formation of LLBs cannot be monitored by measuring levels of drug in the plasma since this special type of accumulation takes place in tissue despite stabilization of plasma drug levels (Hein et al., 1990) .
PNU-177864, a dopamine D3 receptor antagonist, was being considered as a drug candidate for the chronic treatment of schizophrenia. Early assessment of toxicity in a 2-week oral toxicity study in rats showed multifocal to widespread degeneration of myocytes in skeletal muscle. Light microscopic findings suggestive of phospholipid accumulation occurred in skeletal muscle and other tissues, and numerous LLBs were found in affected tissues, including skeletal muscle, examined by transmission electron microscopy (Rudmann et al., 2004) . Comparison of morphologic observations with toxicokinetic profiles showed that LLBs and associated myopathy occurred at doses where plasma drug levels remained essentially constant throughout the 24-hour dosing interval. At doses within the expected therapeutic range, toxicokinetic determinations showed plasma drug level profiles that were considered acceptable for further development of this compound. Although there were no obvious toxicologic effects at these doses, since CADs are known to accumulate in tissues, there was a risk that PNU-177864 or its metabolites would accumulate with long-term dosing causing cellular injury. Therefore, an assessment of drug accumulation in tissues following repeated dosing was done before proceeding with further development of this compound. Vol. 32, No. 3, 2004 CAD-RELATED MYOPATHY 319 Animals and Toxicity Study Designs: The purchase and care of experimental animals and the toxicity study designs and procedures were described previously (Rudmann et al., 2004) . Sprague-Dawley rats [Cr1:CD(SD)BR] were purchased from Charles River Laboratories (Portage, MI). In the main segment of the initial oral toxicity study, groups of rats (5/sex/group) received PNU-177864 orally via gastric gavage, once daily, at doses of 0 (vehicle only), 12.5, 50, and 200 mg/kg/day. Animals in the vehicle control group and in the 12.5 and 50 mg/kg/day groups were dosed for 14 consecutive days. Rats in the 200 mg/kg/day group were dosed for only 9 to 12 days because of severe clinical signs and mortality. All animals were necropsied and tissues were collected and processed for light microscopy.
In the second (electron microscopy) study, groups of 10 male rats received PNU-177864 orally via gastric gavage, once daily, at doses of 0 (vehicle only) or 200 mg/kg/day for 9 days. On Days 3, 6, and 8 of the study, biceps femoris muscle was collected for light and electron microscopy from 2 rats in each group. On Day 9, biceps femoris muscle and other tissues were collected for light and electron microscopy. Tissues were collected following whole body perfusion with fixative. The Institutional Animal Care and Use Committee of Pharmacia & Upjohn approved all experimental protocols.
Toxicokinetics: Blood samples for toxicokinetic determinations were obtained during the initial toxicity study from satellite groups containing 3 animals/sex/dose group. Approximately 250 µl of blood was collected prior to dosing (0 hour) and at 1, 2, 4, 8, and 24 hours postdose on Day 1 and Day 11 (200 mg/kg/day only) or Day 14 (12.5 and 50 mg/kg/day groups). An additional blood sample was collected prior to dosing on Day 7. Blood was also collected at approximately 48 and 168 hours after the final dose of 12.5 and 50 mg/kg/day on Day 14 to monitor plasma levels of PNU-177864 following cessation of dosing. All blood samples were collected into tubes containing EDTA as an anticoagulant and placed on ice. The blood samples were centrifuged within 1 hour after sample collection and the plasma was stored frozen at −10 • C or colder until analyzed for PNU-177864 levels.
Analytical Methodology: Plasma samples were assayed for PNU-177864 by liquid chromatography atmospheric pressure chemical ionization tandem mass spectroscopy (LC-APCI-MS-MS) using a Zorbax 300-SCX strong cation exchange analytical column (4.6 × 50 mm, 5 mm particle size) eluted with a mobile phase of 0.01 M ammonium acetate (pH adjusted to 4.0 with glacial acetic acid):acetonitrile (35:65, volume:volume) at a flow rate of 1.0 ml/min. An appropriate set of calibration standards was prepared in blank rat plasma and an appropriate structural analog was added to all samples as an internal standard. Detection was accomplished with a Finnigan MAT TSQ-700 or a Finnigan MAT-7000 mass spectrometer operated in positive ion APCI mode utilizing selected reaction monitoring. Data were transferred to an internal chromatography system and analyzed. A default value of 0 mg/ml was assigned to plasma samples collected before dosing on Day 1 of the study. The maximum plasma concentration (C max ), the time at which C max occurred (t max ), and the plasma concentration 24 hours after dosing (C 24 ) were obtained by visual inspection of the data. The area under the plasma concentration versus time curve from the first time point to the end of the 24 hr dosing interval (AUC [0-24 hr] ) was calculated using the linear trapezoidal rule (Rowland and Tozer, 1995) . The area under the plasma concentration curve from time zero to infinity (AUC 0-∞ ), on Day 1 of dosing, was calculated using the equation AUC 0−t(last) + C t(last) /λz, where λz, the terminal disposition rate constant, was determined from the linear regression slope of the terminal portion of the log plasma concentration versus time curve. The plasma half-life (t 1/2 ) during the 24-hour dosing period was obtained from 0.693/λz (Rowland and Tozer, 1995) .
Whole Body Autoradiography (WBAR):
Tissue distribution and residence of drug-related radioactivity in rats following oral gavage were evaluated by WBAR and select tissue analysis. Single doses of [ 14 C]PNU-177864 at 200 or 12.5 mg/kg (200 µCi/kg) or doses of 12.5 mg/kg/day (200 µCi/kg loading dose followed by 20 µCi/kg) for either 7 or 14 days were utilized. All animals were euthanized 24 hours after receiving the final dose of drug. One rat from each dose regimen (4 total) was euthanized by CO 2 inhalation, immediately flash-frozen in a dry ice/heptane bath, and prepared for analysis by WBAR. Representative tissue sections (30 µm) were collected from each animal and apposed to phosphor imaging plates for 3 days. The plates were scanned and the resulting images analyzed. The remaining animals were anesthetized by CO 2 inhalation and exsanguinated. Aliquots of skeletal muscle, whole blood, and plasma were collected for analysis by combustion and liquid scintillation counting (LSC).
RESULTS
Light Microscopy: Degenerative changes occurred in skeletal muscles from all high-dose (200 mg/kg/day) animals in the initial toxicity study, but were not found in lower dose groups or in vehicle-treated controls (Figure 2A ). Samples of biceps femoris collected on Day 3 of the second (electron microscopy) toxicity study contained rare vacuolated and fragmented myocytes ( Figure 2B ). By Day 6, treatment-related changes in skeletal muscle were prominent ( Figure 2C ). Scattered myocytes showed slight pallor while others stained intensely eosinophilic. Occasional myocytes contained multiple small round to oval vacuoles or holes, and others showed extensive fragmentation of the sarcoplasm, which frequently contained macrophages and occasional neutrophils. The number and size of sarcoplasmic vacuoles and the number of myocytes affected by vacuolation or fragmentation increased with increasing days of dosing. Numbers of macrophages within myocytes and within the interstitium and the numbers of sarcolemmal nuclei also increased with increasing days of dosing. Examination of skeletal muscle sections collected during both toxicity studies showed that these changes occurred in sections of biceps femoris, triceps, and diaphragm and were often observed in fragments of skeletal muscle adjacent to sections of sternum and stifle joint.
Electron Microscopy: Transmission electron microscopy showed that skeletal muscle from PNU-177864treated rats contained few to numerous, scattered individual or clusters of electron-dense bodies. These were likely lysosomes and were located at the periphery of myocytes adjacent to mitochondria or between myofibrils. They were round to irregular and generally filled with amorphous to lamellar or concentrically arranged electron-dense material characteristic of LLBs ( Figures 3A, 3B) . In some of the bodies, the lamellar material had a scalloped or reticular appearance. Occasional isolated macrophages or collections of macrophages were present within or adjacent to myocytes. The macrophages contained numerous cytoplasmic structures filled with similar amorphous or lamellar electrondense material. The electron-dense bodies in myocytes were visible as dark-blue, sometimes lamellar, droplets in plastic-embedded, toluidine blue-stained, thick sections examined by light microscopy. These likely corresponded with the clear vacuoles seen in myocytes in paraffin-embedded sections examined by light microscopy.
Toxicokinetics: At all doses, the PNU-177864 plasma concentration versus time curve was characterized by a slow absorption phase followed by a sustained distribution and/or elimination phase ( Figures 4A-C) . The apparent terminal half-life increased from 6.5 hours to 16.0 hours between doses of 12.5 and 50 mg/kg/day (Table 1 ). The terminal half-life was not established within the 24-hour dosing period on either Day 1 or Day 11 at the 200 mg/kg/day dose level since plasma concentrations remained essentially constant up to 24 hr after dosing. Comparison of C 24 on Days 1, 7, and 11 or 14 indicated that steady-state plasma concentrations were reached by Day 7 (Table 1) . Following cessation of dosing at 12.5 and 50 mg/kg/day on Day 14 of the study, plasma levels of parent compound were below the limit of detection of the assay by Day 7 of the recovery phase (data not shown).
Whole Body Autoradiography: Results from WBAR after administration of single (200 or 12.5 mg/kg) or multiple doses of 12.5 mg/kg/day are presented in Figures 5A-C. In general, drug-related radioactivity was found widely distributed to most tissues and organs with distinct penetration into brain. Since a loading and maintenance dose were administered to the multiple-dose group, it was assumed that all radioactivity associated with the loading dose (200 µCi/kg) was completely cleared from tissues by Day 7. Therefore, the calibration curve for quantitation of multiple-dosed group tissues was based solely on dosing formulation specific activity. These results indicated that there was an increase of drug-related radioactivity in tissues after 7 daily doses at 12.5 mg/kg/day; however, there was no further increase in tissue concentrations after an additional 7 days of dosing. Combustion analysis of skeletal muscle confirmed WBAR measurements (data not shown).
DISCUSSION
Drug-induced phospholipidosis is caused by a pharmacologically diverse group of compounds collectively designated CADs. These compounds share common structural features, i.e., a hydrophilic portion containing a primary or substituted nitrogen group and a hydrophobic portion consisting of an aromatic and/or aliphatic ring structure often substituted with 1 or more halogen atoms (Halliwell, 1997; Reasor, 1989) . The structure of PNU-177864 is consistent with these features, and the morphologic changes occurring in multiple tissues of rats and dogs following repeated dosing with PNU-177864 (Rudmann et al., 2004) are consistent with drug-induced phospholipidosis. Therefore, PNU-177864 and possibly its metabolites appear to belong to the group of chemicals recognized as phospholipidosis-inducing CADs.
Toxicokinetic evaluations at the high-dose (200 mg/kg/ day) level showed that plasma levels of PNU-177864 remained high and essentially unchanged throughout the 24hour dosing interval. This suggested either continued absorption of parent compound from the gastrointestinal tract or that clearance mechanisms were exceeded. Coincident extensive deposition of drug into body tissues possibly accounted for the observed myocyte injury. At this dose level, the toxicokinetics of PNU-177864 and the observed cellular injury were unacceptable for further development. At lower doses (12.5 and 50 mg/kg/day), which were believed closer to the therapeutic dose, toxicokinetic parameters and the lack of notable toxicologic findings were considered supportive of further development. However, the known tendency of CADs to accumulate in tissues 322 VONDERFECHT ET AL. TOXICOLOGIC PATHOLOGY 1980; Heyneman and Reasor, 1986; Riva et al., 1987; Kannan et al., 1989; Reasor et al., 1990; Kannan et al., 1991) and the inability of routine toxicokinetics to monitor this type of accumulation (Hein et al., 1990) raised concern that PNU-177864 or its metabolites might accumulate in tissues, particularly in skeletal muscle, and that this accumulation would not be detected by determination of levels of PNU-177864 in plasma. Continued accumulation of the parent drug or its metabolites would then result in myocyte injury. This concern was addressed by conducting a multidose drug distribution study using WBAR.
Skeletal muscle (and rarely cardiac muscle) was the only tissue showing morphologic evidence of cellular injury following treatment of rats with repeated high doses (200 mg/kg/day) of PNU-177864. Whole body autoradiography indicated that this could not be attributed simply to exceptionally high levels of parent drug or metabolites in this tissue since skeletal muscle had low levels of drug-related radioactivity when compared with other tissues following a single administration of the compound at the high-dose level. However, it cannot be excluded that parent drug or metabolites accumulated preferentially in muscle after repeated dosing at high doses since autoradiography was done only following a single dose at this level. Whole body autoradiography at the low-dose level (12.5 mg/kg/day) suggested that preferential accumulation did not occur. Tissues having low levels of drug-related material following a single dose of 200 mg/kg generally had low levels of radioactivity after a single dose at 12.5 mg/kg, and radioactivity in these tissues tended to remain low relative to other tissues following multiple days of dosing. Levels of drug-related radioactivity in skeletal muscle reached steady state by Day 7 and exceeded only those in brain 1, 7, and 14 days following repeated dosing at 12.5 mg/kg/day.
Drug-induced phospholipidosis, as indicated by the presence of LLBs, occurred in numerous tissues of rats and dogs given repeated high doses of PNU-177864 (Rudmann et al., 2004) . However, cellular injury was associated with the lamellar bodies only in skeletal muscle. The observation of severe degenerative changes in myocytes is difficult to reconcile with the absence of significant cellular changes observed by transmission electron microscopy. Although accumulation of LLBs was observed, there were no changes in other organelles or in the sarcoplasm that appeared sufficient to account for the severe changes seen by light microscopy. Myopathy has been recognized following treatment with several CADs (Fardeau et al., 1979; Kumamoto et al., 1989; Roth et al., 1990; Schmalbruch, 1980; Horn et al., 1996; Nucci et al., 1996; Yano et al., 2002) . Similar to the observations with PNU-177864, neither the ultrastructural changes present Figure 5C . Concentration on the Y-axis is in µg-equivalents/g.
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TOXICOLOGIC PATHOLOGY nor the pharmacology of the compounds adequately account for the myotoxic effects of the drugs (Schmalbruch, 1980; Kumamoto et al., 1989) . Cationic amphiphilic drugs may accumulate in lysosomes, inhibit activity of lysosomal enzymes, and bind to phospholipids in membranes in general (Hostetler, 1984; Reasor, 1989) . Resulting cellular alterations may include increases in lysosomal pH (Dean et al., 1984) , impaired proteolysis (Hasilik and Neufeld, 1980; Wibo and Poole, 1974) , effects on the phosphatidylinositol pathway (Sauers et al., 1988) , and effects on cellular membrane fluxes such as endocytosis and receptor cycling (Tolleshaug and Berg, 1979; Tietze et al., 1980) . All of these effects could theoretically occur independently of the formation of LLBs. It has also been suggested that the accumulation of material within lysosomes injures lysosomal membranes and increases their permeability or makes the lysosomes fragile (Kumamoto et al., 1989) . Subsequent leakage of proteolytic enzymes into the cytoplasm could damage myofibrils. However, other studies have failed to demonstrate that LLBs show altered permeability (Stäubli et al., 1978) , and electron microscopy of myocytes in the present study did not show myofibrillar damage. The decisions to conduct toxicity studies required for clinical testing and to perform a variety of other activities accompanying development of a pharmaceutical candidate are accompanied by commitments that are time and resource intensive. The observation of severe skeletal muscle changes in rats given PNU-177864 and the concern that these could result from accumulation of the parent drug or metabolites in this tissue were serious complications for continued development of this compound. These issues were addressed by conducting a repeat-dose drug distribution study using WBAR. The study was small, done quickly, and provided data on which to make development decisions. It showed that accumulation of parent drug and metabolites was unlikely at dose levels considered within the pharmacologic range. Moreover, with the advent of rapid mechanisms of tritiation, it is anticipated that WBAR will be incorporated into the discovery testing paradigm for both efficacy and toxicity issues. Based on the findings from this study, development of the compound was continued and 4-week, Good Laboratory Practicesregulated toxicity studies were done in rats and dogs. Minor vacuolation of myocytes occurred only in the highdose (80 mg/kg/day) group in that study (Rudmann et al., 2004) . Before additional studies were done, this therapeutic target was dropped from development for business-related reasons.
